An interventional study of Lercanidipine in Hypertension, sponsored by UCB Pharma. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-03-10.
Sponsored by UCB Pharma · Not applicable and Interventional
A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 180 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →UCB Pharma is the lead sponsor of 238 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
change from baseline of systolic blood pressure (BPs) after 4 weeks of treatment
Blood pressure, response rate, normalization rate, pulse rate, lipid profile, safety and tolerability. Measures after 4, 8, 12 weeks.
No study locations are listed for this record.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UCB Pharma